Cargando…

Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles

ISSUE/PROBLEM: Vaccines are an important public health intervention protecting the population against infectious diseases. The value of vaccines is broad ranging from individual to societal as achieving community immunity protects the unvaccinated, minimizes the risk of outbreaks, reduces the emerge...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, E, D'Agostino, P, Chapman, R, Largeron, N, Louette, L, Sabale, U, Schaible, K, Quilici, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594045/
http://dx.doi.org/10.1093/eurpub/ckac129.328
_version_ 1784815315469729792
author Beck, E
D'Agostino, P
Chapman, R
Largeron, N
Louette, L
Sabale, U
Schaible, K
Quilici, S
author_facet Beck, E
D'Agostino, P
Chapman, R
Largeron, N
Louette, L
Sabale, U
Schaible, K
Quilici, S
author_sort Beck, E
collection PubMed
description ISSUE/PROBLEM: Vaccines are an important public health intervention protecting the population against infectious diseases. The value of vaccines is broad ranging from individual to societal as achieving community immunity protects the unvaccinated, minimizes the risk of outbreaks, reduces the emergence of antimicrobial resistance, and leads to broader societal benefits. DESCRIPTION OF THE PROBLEM: Vaccines’ market access processes are characterized by the development of recommendations by NITAGs followed by the assessment of health technology assessment (HTA) bodies in less than half of 27 EU member states. Despite that HTA for therapeutic drugs is well established, there is very limited experience in applying HTA methodologies to vaccines, especially for clinical assessments, as HTA methods and frameworks are traditionally geared toward therapeutics. However, following the adoption of the EU regulation on HTA, Joint Clinical Assessments (JCAs) of vaccines are expected. RESULTS: To support a discussion on how to account for vaccine specificities in the JCA, Vaccines Europe has performed a project which aimed at developing a proposal for high-level guiding principles on processes and methodologies for clinical HTA for vaccines. The proposal is informed by findings of literature reviews on currently applied processes, methods, and clinical assessment frameworks of vaccines as well as the outcomes of an advisory board with scientific experts. LESSONS: A proposal for high-level guiding principles for clinical HTA for vaccines is being developed based on both evidence and the advice from scientific experts which focuses on processes (e.g., horizon scanning, early advice, consideration of vaccine-specific expertise) and methods (e.g., unmet need, safety, efficacy/effectiveness, real-world evidence and technical characteristics of the technology). Lastly, the implementation of vaccines specificities in JCA represents a call for action.
format Online
Article
Text
id pubmed-9594045
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95940452022-11-22 Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles Beck, E D'Agostino, P Chapman, R Largeron, N Louette, L Sabale, U Schaible, K Quilici, S Eur J Public Health Parallel Programme ISSUE/PROBLEM: Vaccines are an important public health intervention protecting the population against infectious diseases. The value of vaccines is broad ranging from individual to societal as achieving community immunity protects the unvaccinated, minimizes the risk of outbreaks, reduces the emergence of antimicrobial resistance, and leads to broader societal benefits. DESCRIPTION OF THE PROBLEM: Vaccines’ market access processes are characterized by the development of recommendations by NITAGs followed by the assessment of health technology assessment (HTA) bodies in less than half of 27 EU member states. Despite that HTA for therapeutic drugs is well established, there is very limited experience in applying HTA methodologies to vaccines, especially for clinical assessments, as HTA methods and frameworks are traditionally geared toward therapeutics. However, following the adoption of the EU regulation on HTA, Joint Clinical Assessments (JCAs) of vaccines are expected. RESULTS: To support a discussion on how to account for vaccine specificities in the JCA, Vaccines Europe has performed a project which aimed at developing a proposal for high-level guiding principles on processes and methodologies for clinical HTA for vaccines. The proposal is informed by findings of literature reviews on currently applied processes, methods, and clinical assessment frameworks of vaccines as well as the outcomes of an advisory board with scientific experts. LESSONS: A proposal for high-level guiding principles for clinical HTA for vaccines is being developed based on both evidence and the advice from scientific experts which focuses on processes (e.g., horizon scanning, early advice, consideration of vaccine-specific expertise) and methods (e.g., unmet need, safety, efficacy/effectiveness, real-world evidence and technical characteristics of the technology). Lastly, the implementation of vaccines specificities in JCA represents a call for action. Oxford University Press 2022-10-25 /pmc/articles/PMC9594045/ http://dx.doi.org/10.1093/eurpub/ckac129.328 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Parallel Programme
Beck, E
D'Agostino, P
Chapman, R
Largeron, N
Louette, L
Sabale, U
Schaible, K
Quilici, S
Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles
title Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles
title_full Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles
title_fullStr Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles
title_full_unstemmed Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles
title_short Accounting for vaccines specificities in the Joint Clinical Assessment (JCA): a proposal for guiding principles
title_sort accounting for vaccines specificities in the joint clinical assessment (jca): a proposal for guiding principles
topic Parallel Programme
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594045/
http://dx.doi.org/10.1093/eurpub/ckac129.328
work_keys_str_mv AT becke accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples
AT dagostinop accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples
AT chapmanr accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples
AT largeronn accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples
AT louettel accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples
AT sabaleu accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples
AT schaiblek accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples
AT quilicis accountingforvaccinesspecificitiesinthejointclinicalassessmentjcaaproposalforguidingprinciples